Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study

CANDOR (NCT03158688) is a phase 3, randomized, open-label trial comparing carfilzomib, daratumumab, and dexamethasone (KdD) vs carfilzomib and dexamethasone (Kd) in adults with relapsed/refectory multiple myeloma (RRMM) with 1 to 3 prior therapies. The CANDOR study met its primary end point of progr...

Descripción completa

Detalles Bibliográficos
Autores principales: Usmani, Saad Z., Quach, Hang, Mateos, Maria-Victoria, Landgren, Ola, Leleu, Xavier, Siegel, David, Weisel, Katja, Shu, Xiaomei, Li, Chuang, Dimopoulos, Meletios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368773/
https://www.ncbi.nlm.nih.gov/pubmed/37163358
http://dx.doi.org/10.1182/bloodadvances.2023010026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368773/
https://www.ncbi.nlm.nih.gov/pubmed/37163358
http://dx.doi.org/10.1182/bloodadvances.2023010026

Ejemplares similares